FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Patrick Delavault

Research Profile

Chemicals & Drugs

Disorders

Physiology

DNA Repair

Anatomy

Concepts & Ideas

Activities & Behaviors

Internationality

Co-author Network

Publications

TOP 3
Iñaki F Trocóniz; Josep-María Cendrós; Frédérique Cvitkovic; Patrick Delavault; Thierry Lesimple; Concepción Peraire; Ana Perez-Mayoral; Paola Principe; Joan Pruñonosa; Elena Soto; Rosendo Obach
Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors.
Chris Pepper; H Lowe; Christopher Fegan; Christophe Thurieau; D E Thurston; J A Hartley; Patrick Delavault
Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells.
Susannah J Stanway; Patrick Delavault; Atul Purohit; L W Lawrence Woo; Christophe Thurieau; Barry V L Potter; Michael J Reed
Steroid sulfatase: a new target for the endocrine therapy of breast cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Patrick Delavault (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Iñaki F Trocóniz; Josep-María Cendrós; Frédérique Cvitkovic; Patrick Delavault; Thierry Lesimple; Concepción Peraire; Ana Perez-Mayoral; Paola Principe; Joan Pruñonosa; Elena Soto; Rosendo Obach
Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2012;70(2):239-50.
2007: Chris Pepper; H Lowe; Christopher Fegan; Christophe Thurieau; D E Thurston; J A Hartley; Patrick Delavault
Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells.
British journal of cancer 2007;97(2):253-9.
2007: Susannah J Stanway; Patrick Delavault; Atul Purohit; L W Lawrence Woo; Christophe Thurieau; Barry V L Potter; Michael J Reed
Steroid sulfatase: a new target for the endocrine therapy of breast cancer.
The oncologist 2007;12(4):370-4.
2006: Jacques-Pierre Moreau; Patrick Delavault; Joëlle Blumberg
Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
Clinical therapeutics 2006;28(10):1485-508.
2004: Chris Pepper; Rachel M Hambly; Christopher Fegan; Patrick Delavault; David E Thurston
The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill.
Cancer research 2004;64(18):6750-5.
2003: Manfred Westphal; Dana C Hilt; Enoch Bortey; Patrick Delavault; Robert Olivares; Peter C Warnke; Ian R Whittle; Juha Jääskeläinen; Zvi Ram
A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.
Neuro-oncology 2003;5(2):79-88.